MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
271.97
+3.10
+1.15%
Opening 10:00 03/18 EDT
OPEN
270.00
PREV CLOSE
268.87
HIGH
272.59
LOW
269.21
VOLUME
290.25K
TURNOVER
0
52 WEEK HIGH
329.72
52 WEEK LOW
206.75
MARKET CAP
145.75B
P/E (TTM)
21.78
1D
5D
1M
3M
1Y
5Y
Surprising Analyst 12-Month Target For QQQM
NASDAQ · 19h ago
More Big Changes To My Dividend Growth Portfolio
Home Dividends Analysis Dividend Strategy More Big Changes To My Dividending Growth Portfolio. Nicholas Ward has been actively reshaping his portfolio by selling off low-conviction holdings. He has reduced his holdings from 90 to 70 in the past 6 months. Ward believes his changes will set up his portfolio for continued double-digit income growth.
Seeking Alpha · 20h ago
Weekly Report: what happened at AMGN last week (0311-0315)?
Weekly Report · 22h ago
Relative Strength Alert For Amgen
NASDAQ · 3d ago
Dow Movers: CRM, AMGN
NASDAQ · 3d ago
Terns to report Phase 1 data on GLP-1 drug in 2H 2024
Terns Pharmaceuticals to report Phase 1 data on GLP-1 drug in the treatment of obesity in the second half of 2024. The biotech company also expects to release interim data from its drug for chronic myelogenous leukemia in 2024. Terns is one of several companies working on drugs for weight loss. The company's quarterly earnings report met expectations.
Seeking Alpha · 4d ago
UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates
Healthcare UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates. Eli Lilly’s drug tirzepatide in the treatment of sleep apnea will come in below Street expectations. UBS said it sees the study demonstrating weight loss of 12-14% and AHI reduction of 30-37% from baseline.
Seeking Alpha · 4d ago
Notable ETF Outflow Detected - MTUM, AMGN, INTU, CRWD
NASDAQ · 4d ago
More
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness. It also offers TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase) and UPLIZNA (inebilizumab-cdon).

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.